| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $1,544,196 ) |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA258778 | Targeting tumor-associated macrophages for triple-negative breast cancer treatment | 000 | 4 | NIH | 11/12/2024 | $467,633 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA241845 | Validation of epigenomic biomarkers for thyroid cancer diagnostics | 000 | 4 | NIH | 11/13/2024 | $737,207 |
| | 2025 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01DK134652 | Role of trefoil factor family proteins in beta cell function. | 000 | 3 | NIH | 11/13/2024 | $511,289 |
| | 2025 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA258981 | The Role of miR-142 in the Transformation of Clonal Hematopoietic Disorders into AML | 000 | 3 | NIH | 11/8/2024 | $0 |
| | 2025 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA286160 | Targeting Immune Escape in CML/MPN Transformation | 000 | 1 | NIH | 10/30/2024 | $0 |
| | 2025 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | U24DK104162 | Renewal of the Human Islet Research Enhancement Center (HIREC) for the Type-1-Diabetes-Focused Human Islet Research Network (HIRN). | 000 | 11 | NIH | 10/23/2024 | $0 |
| | 2025 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | U24DK104162 | Renewal of the Human Islet Research Enhancement Center (HIREC) for the Type-1-Diabetes-Focused Human Islet Research Network (HIRN). | 000 | 11 | NIH | 10/23/2024 | $0 |
| | 2025 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01NS134116 | Improving Glioma Immunotherapy Efficacy by Regulating Tumor Inflammation | 000 | 2 | NIH | 10/24/2024 | $0 |
| | 2025 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA247550 | Characterizing and Targeting the Novel IL-15- AKT-XBP1s Pathway in NK Cells | 000 | 5 | NIH | 10/18/2024 | -$171,933 |
| | 2025 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01NS106170 | Overcoming Barriers of Virotherapy by Next-Generation oHSV Expressing E-Cadherin | 000 | 5 | NIH | 10/28/2024 | $0 |
| | 2025 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | K99AI159139 | Immune Evasion Mechanisms of KSHV Complement and Fc-Receptor Proteins | 000 | 2 | NIH | 10/24/2024 | $0 |
| | 2025 | 2022 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R21CA261797 | Remote monitoring of cardiac function in childhood cancer survivors | 000 | 2 | NIH | 11/5/2024 | $0 |
| | 2025 | 2021 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R21AI161075 | Develop novel inhaled neutralizing RNA therapeutics against COVID-19 | 000 | 1 | NIH | 11/7/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $77,354,323 ) (Continued on the next page) |
| | 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R37CA276517 | Targeting the long isoform of the prolactin receptor to treat autoimmune diseases and B-cell malignancies | 000 | 2 | NIH | 7/5/2024 | $416,328 |
| | 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA256989 | Elucidating the role of DNAPKcs in chromosomal break end joining and clastogen resistance | 001 | 4 | NIH | 6/25/2024 | $382,471 |
| | 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | U01CA264620 | Mechanism of estrogen independent proliferation in ER+ breast cancer cells | 003 | 4 | NIH | 8/8/2024 | $519,329 |
| | 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | U01CA214254 | Exosome-based microRNA biomarkers for Non-invasive and Early Detection of Pancreatic Cancer | 003 | 7 | NIH | 8/8/2024 | $815,080 |
| | 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01HL164895 | A Novel Bone Marrow Transplantation Approach for Sickle Cell Disease Using Targeted Marrow Irradiation | 000 | 2 | NIH | 6/14/2024 | $343,450 |
| | 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA241845 | Validation of epigenomic biomarkers for thyroid cancer diagnostics | 002 | 3 | NIH | 7/26/2024 | $267,000 |
| | 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | UM1CA186717 | Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTN | 004 | 8 | NIH | 7/16/2024 | $0 |
| | 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R25CA275711 | Cancer Aging and Metabolism research experience Program (CAMP) | 000 | 1 | NIH | 6/21/2024 | $240,924 |
| | 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R13CA294952 | 21st International Conference of the Society for Integrative Oncology | 001 | 1 | NIH | 8/16/2024 | $5,000 |
| | 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01AI146313 | The role of miR-142 in regulatory T cell Development and function | 000 | 5 | NIH | 8/16/2024 | $440,000 |
| | 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01HL162847 | Pathogenesis, prevention and treatment of corticosteroid-resistant gut GVHD | 001 | 2 | NIH | 6/21/2024 | $68,537 |
| | 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA272732 | Development of Microbial-Based Therapies to Suppress Macropinocytosis in Kras-Driven Cancers | 000 | 3 | NIH | 6/21/2024 | $382,471 |
| | 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01HL150069 | Cardiovascular reserve capacity in survivors of hematopoietic cell transplantation | 001 | 5 | NIH | 6/21/2024 | $56,038 |
| | 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA271497 | The role and therapeutic potential of IGF2BP2 in MLL-rearranged leukemia | 001 | 3 | NIH | 4/17/2024 | $28,680 |
| | 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R37CA284040 | Examining the Impact of Structural Racism on African American Non-Small Cell Lung Cancer Mutational Signatures and Outcomes | 000 | 1 | NIH | 5/13/2024 | $1,027,816 |
| | 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R00CA256526 | Investigating the Role of Radiation-induced Cell Death in Innate Lymphoid Cell Activation within Unique Tumor Microenvironments | 001 | 4 | NIH | 4/17/2024 | $24,901 |
| | 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01AI151013 | KSHV Subunit Vaccine Candidates to Elicit Potent Humoral Immune Reponses against KSHV Infection | 001 | 4 | NIH | 5/23/2024 | $84,892 |
| | 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R37CA233691 | Combinational Targeting the Feed-forward Epigenetic Circuitry in Mixed Lineage Leukemia | 001 | 6 | NIH | 6/6/2024 | $20,129 |
| | 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R21AI168750 | Use of a non-human primate model to define the role of T cell immune responses in persistent Kaposi sarcoma-associated herpesvirus infection and Kaposi sarcoma pathogenesis | 001 | 2 | NIH | 5/22/2024 | $32,652 |
| | 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA258981 | The Role of miR-142 in the Transformation of Clonal Hematopoietic Disorders into AML | 001 | 3 | NIH | 4/18/2024 | $27,144 |
| | 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA241845 | Validation of epigenomic biomarkers for thyroid cancer diagnostics | 001 | 3 | NIH | 4/17/2024 | $41,021 |
| | 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA278050 | Mechanism and therapeutic opportunities of targeting the Tudor domain | 001 | 2 | NIH | 4/18/2024 | $25,564 |
| | 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01ES034793 | Early Life Exposure to Endocrine Disrupting Chemicals: Epigenomic and Transcriptomic Networks and RAGE in Liver Disease | 000 | 1 | NIH | 4/17/2024 | $767,662 |
| | 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | T32DK131943 | DIABETES PREVENTION / RISK / OMICS / METABOLISM / THERAPY (PROMT) INTERDISCIPLINARY TRAINING | 001 | 2 | NIH | 4/30/2024 | $7,530 |
| | 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01AG072291 | Develop age-relevant glial cellular models using human directly reprogrammed cells | 000 | 4 | NIH | 5/21/2024 | $440,000 |
| | 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01LM013876 | An integrated toolkit combining computational systems biology techniques with molecular dynamics simulations to delineate functionality of GPCRs | 000 | 3 | NIH | 3/22/2024 | $336,600 |
| | 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01LM013876 | An integrated toolkit combining computational systems biology techniques with molecular dynamics simulations to delineate functionality of GPCRs | 001 | 3 | NIH | 5/8/2024 | $37,400 |
| | 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA254271 | Clinical Evaluation of Chlorotoxin-redirected Chimeric Antigen Receptor (CAR) T cells for Treatment of Glioblastoma | 000 | 5 | NIH | 4/11/2024 | $711,759 |
| | 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01DK134652 | Role of trefoil factor family proteins in beta cell function. | 001 | 2 | NIH | 5/8/2024 | $34,086 |
| | 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA243386 | Targeting FTO to treat acute myeloid leukemia | 001 | 5 | NIH | 4/16/2024 | $28,529 |
| | 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA073764 | FEN1-mediated Okazaki fragment maturation and its deficiency in cancer | 001 | 26 | NIH | 5/2/2024 | $445,000 |
| | 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | UM1CA186717 | Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTN | 003 | 8 | NIH | 4/15/2024 | $1,293,587 |
| | 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA269569 | BAFF-R CAR T cell therapy for ALL | 001 | 3 | NIH | 4/25/2024 | $33,881 |
| | 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | F32CA290941 | Development of novel CYP8B1 inhibitors | 001 | 1 | NIH | 4/1/2024 | $0 |
| | 2024 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | F32CA290941 | Development of novel CYP8B1 inhibitors | 000 | 1 | NIH | 4/1/2024 | $69,500 |
|
